Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)

Inclusion Criteria: * Women with newly diagnosed histologically confirmed FIGO Stage IB-IVA carcinoma of the cervix, including squamous, adenosquamous or adenocarcinoma. Women not suitable for surgery due to comorbidities (medical or other conditions) are also considered eligible. * Age equal to or greater than 18 years * Being considered for treatment with curative intent using concurrent chemotherapy and pelvic RT. Exclusion Criteria: * ECOG performance status greater than 2. * Other cervical cancer tumour types (e.g. neuroendocrine, serous). * Carcinoma of the cervical stump. * Prior hysterectomy. * Patients who, at the time of the initial evaluation, have already undergone a whole body PET-CT within the last 6 months. * Contraindications to 18FDG PET-CT or CT of the abdomen and pelvis. * Inability to lie supine for imaging with PET-CT. * Contraindication to radiotherapy (i.e., significant Crohn's disease). * Contraindication to cisplatin chemotherapy (i.e., non-reversible renal failure). * Inadequate bone marrow function: ANC less than 1.5 X 10\^9, platelets less than 100 X 10\^9. * Inadequate renal function: Creatinine greater/equal to 150 micromol/L * Inadequate hepatic function: Bilirubin greater than 1.5 X ULN and SGOT and Alkaline Phosphatase greater than 3 X ULN. * History of another invasive malignancy within the previous 5 years with the exception of non-melanoma skin cancer. * Other medical conditions that may preclude chemo-radiation therapy. * Known pregnancy or lactating. * Inability to complete study or required follow-up.